Lung cancer Posts on Medivizor
Navigation Menu

Lung cancer Posts on Medivizor

Comparing surgery alone and surgery plus chemotherapy for limited-stage small-cell lung cancer

Comparing surgery alone and surgery plus chemotherapy for limited-stage small-cell lung cancer

Posted by on Jul 21, 2021 in Lung cancer | 0 comments

In a nutshell This analysis was carried out to assess the outcomes of patients who underwent surgery only or surgery and chemotherapy (CT) for limited-stage small-cell lung cancer (LS-SCLC). The authors found that surgery plus CT resulted in better outcomes compared to surgery alone.  Some background SCLC is an aggressive type of...

Read More

Comparing lobectomy and sublobar resection for older patients with stage 1A NSCLC

Comparing lobectomy and sublobar resection for older patients with stage 1A NSCLC

Posted by on Jul 11, 2021 in Lung cancer | 0 comments

In a nutshell The study was carried out to assess the difference in outcomes between lobectomy (LE) and sub-lobar resection (SLR) for older patients with stage I non-small-cell lung cancer (NSCLC). The authors found that both surgeries had similar outcomes in these patients.  Some background NSCLC is responsible for 85% of lung cancer diagnoses...

Read More

Comparing the outcomes of robot-assisted versus video-assisted thoracic surgery for patients with non-small cell lung cancer.

Comparing the outcomes of robot-assisted versus video-assisted thoracic surgery for patients with non-small cell lung cancer.

Posted by on Jun 30, 2021 in Lung cancer | 0 comments

In a nutshell This study compared the short-term and long-term effectiveness between video-assisted thoracic surgery (VATS) and robot-assisted thoracic surgery (RATS) for the treatment of patients with non-small cell lung cancer (NSCLC). The data showed that RATS is a good and safe technique compared with VATS in terms of short-term and long-term...

Read More

Does high dose of thoracic radiotherapy improve the survival of patients with limited-stage small cell lung cancer?

Does high dose of thoracic radiotherapy improve the survival of patients with limited-stage small cell lung cancer?

Posted by on Jun 13, 2021 in Lung cancer | 0 comments

In a nutshell The study aimed to investigate the safety, tolerability, and effectiveness of high-dose thoracic radiotherapy for limited-stage (LS) small-cell lung cancer patients (SCLC). The study concluded the high dose of thoracic radiotherapy improved the survival of these patients without increasing toxicity.  Some background Lung cancer...

Read More

Should SBRT be added to TKI treatment for advanced EGFR-positive non-small cell lung cancer?

Should SBRT be added to TKI treatment for advanced EGFR-positive non-small cell lung cancer?

Posted by on Jun 5, 2021 in Lung cancer | 0 comments

In a nutshell This trial was carried out to assess the effectiveness of EGFR-tyrosine kinase inhibitors (TKIs) with stereotactic body radiation therapy (SBRT) in advanced non-small-cell lung cancer (NSCLC). The authors found that TKIs plus SBRT improved the survival without disease worsening for these patients.  Some background Lung cancer...

Read More

Should chemotherapy be used with EGFR-TKIs as a first-line treatment for advanced NSCLC?

Should chemotherapy be used with EGFR-TKIs as a first-line treatment for advanced NSCLC?

Posted by on Jun 5, 2021 in Lung cancer | 0 comments

In a nutshell This review was carried out to analyze the effectiveness and safety of EGFR tyrosine kinase inhibitors (TKIs) plus chemotherapy (CT) versus EGFR-TKIs alone as a treatment for advanced non-small-cell lung cancer (NSCLC) that is EGFR-positive. The authors found that EGFR-TKIs and CT treatment improved survival for these patients while...

Read More

Comparing alectinib to ceritinib treatment for ALK-positive non-small-cell lung cancer that failed after crizotinib treatment

Comparing alectinib to ceritinib treatment for ALK-positive non-small-cell lung cancer that failed after crizotinib treatment

Posted by on May 30, 2021 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness of ceritinib (Zykadia) and alectinib (Alecensa) in patients with ALK-positive non-small-cell lung cancer (NSCLC) who previously had a crizotinib (Xalkori) treatment failure. The data showed that both ceritinib and alectinib were effective in these patients. Some background Non-small-cell lung cancer...

Read More

Comparing PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer.

Comparing PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer.

Posted by on May 30, 2021 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety outcomes of programmed death-1 (PD-1)/PD ligand 1 (PD-L1) inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer (NSCLC). The data showed that PD-1/PD-L1 inhibitors were safer and more effective than chemotherapy in these patients. Some...

Read More

Does pembrolizumab improve survival of patients with metastatic non-small-cell lung cancer in the long term?

Does pembrolizumab improve survival of patients with metastatic non-small-cell lung cancer in the long term?

Posted by on May 23, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated the long-term effectiveness of pembrolizumab (Keytruda) in patients with untreated metastatic non-small cell lung cancer (NSCLC). The authors showed that pembrolizumab increased the long-term survival of patients compared to chemotherapy. Some background NSCLC accounts for most lung cancers....

Read More

Should cemiplimab be considered a first-line treatment for advanced non-small-cell lung cancer?

Should cemiplimab be considered a first-line treatment for advanced non-small-cell lung cancer?

Posted by on May 23, 2021 in Lung cancer | 0 comments

In a nutshell This study aimed to examine the effectiveness and safety of cemiplimab (Libtayo) in the first-line treatment of patients with advanced non-small-cell lung cancer (NSCLC) with a high quantity of PD-L1 protein. The study concluded cemiplimab improved survival of these patients compared to standard chemotherapy. Some background NSCLC...

Read More

Should radiotherapy be given at the same time or after chemotherapy for patients with advanced non-small cell lung cancer?

Should radiotherapy be given at the same time or after chemotherapy for patients with advanced non-small cell lung cancer?

Posted by on May 22, 2021 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety outcomes of radiotherapy given at the same time (concurrent chemoradiotherapy; cCRT) or after chemotherapy (sequential chemoradiotherapy; sCRT) for the treatment of patients with advanced non-small-cell lung cancer (NSCLC). The data showed that cCRT improved the long-term...

Read More

Could immune-related adverse events predict the effectiveness of immune checkpoint inhibitors in patients with lung cancer?

Could immune-related adverse events predict the effectiveness of immune checkpoint inhibitors in patients with lung cancer?

Posted by on May 16, 2021 in Lung cancer | 0 comments

In a nutshell This study investigated whether immune-related side effects (irSEs) could predict the effectiveness of immune checkpoint inhibitors (ICIs) in patients with lung cancer. The data showed that the occurrence of skin, hormone, and gastrointestinal irSEs could predict the effectiveness of immunotherapy in these patients. Some background...

Read More